Verrica Pharmaceuticals financials
$4.46−3.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M | $5.0M | $5.1M | $14.3M | $12.7M | $3.4M | $344.0K | -$1.8M | $5.2M | $3.8M | $2.0M | $2.9M |
| Gross profit | $5.0M | $4.1M | $3.7M | $13.2M | $12.2M | $3.0M | -$281.0K | -$2.2M | $4.6M | $2.7M | $1.7M | $2.6M |
| Gross margin | 85.0% | 82.3% | 72.5% | 92.3% | 96.1% | 87.3% | −81.7% | 124.4% | 89.5% | 70.3% | 86.3% | 90.7% |
| Operating income | -$13.1M | -$9.7M | -$6.9M | $1.6M | $1.5M | -$8.1M | -$11.3M | -$20.7M | -$15.2M | -$18.6M | -$20.6M | -$23.9M |
| Net income | -$13.2M | -$9.7M | -$8.1M | -$274.0K | $204.0K | -$9.7M | -$16.2M | -$22.9M | -$17.2M | -$20.3M | -$24.6M | -$24.8M |
| Net margin | −224.4% | −192.8% | −158.6% | −1.9% | 1.6% | −283.3% | −4709.9% | 1283.5% | −332.0% | −531.4% | −1238.1% | −850.3% |
| Diluted EPS | $-0.62 | $-0.45 | $-0.57 | $-0.03 | $0.02 | $-1.03 | $-1.07 | $-4.88 | $-3.70 | $-4.40 | $-5.31 | $-5.40 |
| EBITDA | -$11.4M | -$9.7M | -$6.9M | $1.6M | $1.6M | -$8.1M | -$11.3M | -$20.6M | -$15.2M | -$18.3M | -$20.4M | -$23.8M |
| Operating cash flow | -$9.3M | -$9.2M | -$4.6M | $9.7M | -$10.0M | -$12.7M | -$16.1M | -$8.6M | -$16.4M | -$19.9M | -$14.5M | -$14.8M |
| Free cash flow | -$9.3M | -$9.2M | -$4.6M | $9.7M | -$10.0M | -$12.7M | -$16.1M | -$8.6M | -$16.4M | -$19.9M | -$14.7M | -$14.9M |
| Diluted shares | 21.3M | 21.3M | 14.1M | 9.5M | 9.5M | 9.5M | 15.1M | 4.7M | 4.7M | 4.6M | 4.6M | 4.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.2M | $20.6M | $30.1M | $21.1M | $15.4M | $29.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $1.4M | $942.0K | $1.0M | $35.1M | $38.1M | $41.6M |
| Total assets | $36.0M | $38.8M | $47.1M | $40.9M | $39.1M | $42.2M |
| Total liabilities | $31.7M | $22.7M | $22.4M | $57.9M | $56.6M | $60.8M |
| Shareholders' equity | $4.3M | $16.1M | $24.7M | -$17.0M | -$17.5M | -$18.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology